Neoadjuvant L19IL2/L19TNF- Pivotal Study

NCT02938299 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: L19IL2 + L19TNF
PROCEDURE: Surgery

Sponsor

Philogen S.p.A.